Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Regeneron Pharmaceuticals Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.57 (market cap $94.46M), while Regeneron Pharmaceuticals Inc trades at $747.26 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 806.1× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MSTZ | REGN | |
|---|---|---|
Market Cap | $94.46M | $76.14B |
Volume | 104,717,733 | 500,239 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $852.03 |
52-Week Low | $2.29 | $557.73 |
Typical Hold Time | 8 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ is trading at $2.54, down 4.51% today, with technical indicators showing a bearish trend as moving averages signal selling pressure. The stock lacks key financial ratio data, making fundamental assessment challenging. Recent ETF coverage highlights its inclusion in leveraged/inverse ETF discussions, though specific company performance details are limited.
The outlook remains cautious due to incomplete financial disclosures and bearish technical signals. Investment opportunities depend on forthcoming earnings clarity, while risks include volatility from limited institutional coverage and market sentiment shifts. Investors should await detailed financial updates for informed decisions.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
